

Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022

<https://marketpublishers.com/r/RD23B0B203FEN.html>

Date: November 2017

Pages: 40

Price: US\$ 2,400.00 (Single User License)

ID: RD23B0B203FEN

Abstracts

DESCRIPTION

Measles, mumps and rubella are acute respiratory infectious diseases caused by viruses, all of which can be spread through droplets coming from respiratory tracts. Children and teenagers are high risk groups of diseases. Breakout of epidemics among groups will not only result in harms to their health but also have a direct impact on normal teaching orders and even cause social panics.

Measles has the highest incidence rate and mortality rate, posing extremely huge threats to children's health. People infected with measles usually have clinic manifestations like fever, rashes and cold. Although rubella and mumps exhibit slight clinic symptoms and favorable prognosis, mumps sometimes brings about serious complications, such as boys with secondary orchitis and girls with secondary oophoritis, further leading to sterility and infertility when they grow up. If women are infected with measles at the early stage of pregnancy, there is a possibility of abortion and fetal malformation.

CRI analyzes that despite reduced incidence rates of measles, rubella and mumps in China in recent years, there is still a big gap between the actual incidence rate of measles and the targeted incidence rate set by WHO, which is required to be less than 1/ 1 million people.

In 2012, China's incidence rate of measles was recorded the lowest, which was only 4.6/ 1 million people, but this rate has shown an uptrend since 2013. The incidence rates of rubella and mumps demonstrated an overall declining trend between 2012 and 2016.

According to CRI, there have been four mainstream vaccines related to measles, rubella and mumps in China by the end of 2017. (1) Measles live attenuated vaccines: five enterprises hold production permits. (2) Measles-mumps combined live attenuated vaccines: two enterprises hold production permits. (3) Measles-rubella combined live attenuated vaccines: two enterprises hold production permits. (4) Measles-mumps-rubella combined live attenuated vaccine (measles-mumps-rubella vaccine): two enterprises hold production permits. In addition, imported measles-mumps-rubella vaccines produced by Glaxo SmithKline are launched into the Chinese market, namely Priorix. Although several enterprises possess production permits of MMR vaccines in China, a part of them have ceased production.

Research by CRI suggests that the sales volume of MMR vaccines exhibited a fluctuating trend in China between 2013 and 2017. This fluctuation is mainly attributed to factors such as government policies and market demand. In 2016, the sales volume of MMR vaccines exceeded 70 million.

The MMR vaccine is gradually taking up the market shares of other vaccines because of its good effect, preventing three types of infectious diseases.

Since 2008, the domestic MMR vaccine has been included in China's planned immunization, and provided free for children of appropriate ages by the government. This measure has promoted the development of the MMR vaccine industry in China. From a long-term perspective, MMR vaccines are expected to be the mainstream products, which will gradually substitute monovalent and combined vaccines.

CRI predicts a promising prospect of the MMR vaccine market since the loosening birth control policy is projected to contribute to an annual newborn population of 20 million or more in China during 2018 and 2022. It is estimated that the market shares of MMR vaccines will rise from 70% in 2017 to over 90% in 2022.

Readers can obtain the following information or more through this report:

Government Policies of China MMR Vaccines

Supply Status of MMR Vaccines in China

Lot Release Status of MMR Vaccines

Demand Status of MMR Vaccines in China

MMR Vaccine Manufacturers in China

Competition in China MMR Vaccine Industry

Market Opportunities and Driving Forces of China MMR Vaccine Industry

Risks and Challenges Faced by China MMR Vaccine Industry

Prospect of China MMR Vaccine Market, 2018-2022

Contents

1 DEVELOPMENT ENVIRONMENT OF CHINA VACCINE INDUSTRY, 2015-2018

- 1.1 Economic Environment
- 1.2 Policy Environment of China Vaccine Industry
 - 1.2.1 Primary Policies
 - 1.2.2 Lot Release System
- 1.3 Population Size and Structure in China
- 1.4 Overview of China Medical Industry
- 1.5 Overview of China Vaccine Market

2 OVERVIEW OF CHINA MMR VACCINE MARKET, 2013-2017

- 2.1 Epidemic Situations of Measles, Mumps and Rubella in China
 - 2.1.1 Measles
 - 2.1.2 Mumps
 - 2.1.3 Rubella
 - 2.1.4 MMR Vaccine
- 2.2 Rules of Vaccination Procedures of China National Immunization Program

3 ANALYSIS ON CHINA MMR VACCINE MARKET, 2013-2017

- 3.1 Status of Lot Release
 - 3.1.1 Measles Live Attenuated Vaccine
 - 3.1.2 Measles-Mumps Combined Live Attenuated Vaccine
 - 3.1.3 Measles-Rubella Combined Live Attenuated Vaccine
 - 3.1.4 Measles-Mumps-Rubella (Combined) Vaccine
- 3.2 Market Scale
 - 3.2.1 Market Size of Measles Live Attenuated Vaccines
 - 3.2.2 Market Size of Measles-Rubella Combined Live Attenuated Vaccines
 - 3.2.3 Market Size of MMR Combined Live Attenuated Vaccines
- 3.3 Analysis on Competition in China MMR Vaccine Market, 2016-2018
 - 3.3.1 Barriers to Entry
 - 3.3.2 Competition Structure

4 MAJOR MMR VACCINE MANUFACTURERS IN CHINA, 2015-2018

- 4.1 MMR Combined Vaccine

- 4.1.1 Shanghai Institute of Biological Products Co., Ltd.
- 4.1.2 Beijing Tiantan Biological Products Co., Ltd.
- 4.2 Measles Live Attenuated Vaccine
 - 4.2.1 Beijing Bio-Institute Biological Products Co., Ltd.
 - 4.2.2 Changchun Keygen Biological Products Co., Ltd.
 - 4.2.3 Wuhan Institute of Biological Products Co., Ltd.
- 4.3 Measles-Rubella Combined Live Attenuated Vaccine
 - 4.3.1 Beijing Minhai Biological Products Co., Ltd.
 - 4.3.2 Beijing Bio-Institute Biological Products Co., Ltd.
- 4.4 Measles-Mumps Combined Live Attenuated Vaccine
 - 4.4.1 Shanghai Institute of Biological Products Co., Ltd.
 - 4.4.2 Wuhan Institute of Biological Products Co., Ltd.

5 PROSPECT OF CHINA MMR VACCINE MARKET, 2018-2022

- 5.1 Factors Influencing Development
 - 5.1.1 Market Opportunities and Driving Forces
 - 5.1.2 Risks and Challenges
- 5.2 Forecast on Supply of MMR Vaccines in China, 2018-2022
- 5.3 Forecast on Demand for MMR Vaccines in China, 2018-2022

Selected Charts

SELECTED CHARTS

Chart Population Size in China, 2001-2016
Chart Population Structure in China, 2003-2015
Chart Newborn Population in China, 2001-2016
Chart Medical and Health Expenditure in China, 2001-2016
Chart Medical and Healthcare Expenditure Per Capita in China, 2001-2016
Chart Incidence Situation of Measles in China, 2001-2016
Chart Incidence Situation of Rubella in China, 2001-2016
Chart Lot Release Volume of MMR-Type Vaccines in China, 2013-2017
Chart Lot Release Volume of Measles Live Attenuated Vaccines in China, 2012-2017
Chart Lot Release Volume of Measles-Mumps Combined Live Attenuated Vaccines in China, 2012-2017
Chart Lot Release Volume of Measles-Rubella Combined Live Attenuated Vaccines in China, 2012-2017
Chart Lot Release Volume of MMR Vaccines in China, 2012-2017
Chart Market Size of Measles Live Attenuated Vaccines in China, 2013-2017
Chart Market Size of Measles-Rubella Combined Live Attenuated Vaccines in China, 2013-2017
Chart Market Size of MMR Vaccines in China, 2013-2017
Chart Lot Release Volume of MMR Vaccines of Shanghai Institute of Biological Products Co., Ltd., 2010-2017
Chart Production Volume of MMR Vaccines of Beijing Tiantan Biological Products Co., Ltd.
Chart Forecast on Lot Release Volume of MMR Vaccines in China, 2018-2022
Chart Forecast on Market Size of MMR Vaccines in China, 2018-2022

COMPANIES MENTIONED

Shanghai Institute of Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Beijing Bio-Institute Biological Products Co., Ltd.
Changchun Keygen Biological Products Co., Ltd.
Wuhan Institute of Biological Products Co., Ltd.
Beijing Minhai Biological Products Co., Ltd.
Beijing Bio-Institute Biological Products Co., Ltd.
Shanghai Institute of Biological Products Co., Ltd.

Wuhan Institute of Biological Products Co., Ltd.

I would like to order

Product name: Research Report on China's Measles, Mumps and Rubella (MMR) Vaccine Industry, 2018-2022

Product link: <https://marketpublishers.com/r/RD23B0B203FEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RD23B0B203FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

